In this retrospective cohort study, we assessed the clinical relevance of TP53 mutations in breast cancer patients, including all subtypes and treatments, and conducted subgroup analyses based on the characteristics of TP53 mutations within the TP53-mutated group. Here, TP53 is linked to breast carcinoma.